MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage biotechnology company and leader in the development of Microbiome Ecosystem TherapiesTM (MET)[1] to improve survival in cancer patients, today announced that the DSMB has reviewed the safety data from the first 8 Amyotrophic Lateral Sclerosis (ALS) patients treated with MaaT033 in the IASO clinical trial. The DSMB has recommended that the trial continue unchanged. To know more
